| Literature DB >> 24298208 |
A Kaczmarek1, J Cielecka-Piontek, P Garbacki, K Lewandowska, W Bednarski, B Barszcz, P Zalewski, W Kycler, I Oszczapowicz, A Jelińska.
Abstract
The impact of ionizing radiation generated by a beam of electrons of 25-400 kGy on the stability of such analogs of anthracycline antibiotics as daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) was studied. Based on EPR results, it was established that unstable free radicals decay exponentially with the half-time of 4 days in DAU and DOX and 7 days in EPI after irradiation. Radiation-induced structural changes were analyzed with the use of spectrophotometric methods (UV-Vis and IR) and electron microscope imaging (SEM). A chromatographic method (HPLC-DAD) was applied to assess changes in the contents of the analogs in the presence of their impurities. The study showed that the structures of the analogs did not demonstrate any significant alterations at the end of the period necessary for the elimination of unstable free radicals. The separation of main substances and related substances (impurities and potential degradation products) allowed determining that no statistically significant changes in the content of particular active substances occurred and that their conversion due to the presence of free radicals resulting from exposure to an irradiation of 25 kGy (prescribed to ensure sterility) was not observed.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24298208 PMCID: PMC3835845 DOI: 10.1155/2013/258758
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Chemical structures of daunorubicin, doxorubicin, and epidoxorubicin.
Figure 2UV spectra of unirradiated and gamma irradiated daunorubicin.
Figure 3UV spectra of unirradiated and gamma irradiated doxorubicin.
Figure 4UV spectra of unirradiated and gamma irradiated epidoxorubicin.
Main characteristic vibrational modes of daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) observed in experimental and calculated spectra.
| Calculation (cm−1) | Experimental (cm−1) | Band assignment | ||||
|---|---|---|---|---|---|---|
| DAU | DOX | EPI | DAU | DOX | EPI | |
| 723 | 736 | 736 | 764 | 761 | 761 | C–C–C |
|
| ||||||
| 752 | 754 | 749 | 795 | 795 | 795 | NH2
|
|
| ||||||
| 776 | 773 | 774 | 816 | 804 | 805 | C–C–C |
|
| ||||||
| 931 | 930 | 935 | 940 | 939 | 939 | C–O–H |
|
| ||||||
| 959 | 957 | 951 | 955 | 949 | 949 | C–C–C |
|
| ||||||
| 984 | — | — | CH3
| |||
|
| ||||||
| 1010 | 1008 | 1006 | 986 | 990 | 989 | Breathing aglycone group + CH2
|
|
| ||||||
| 1021 | 1029 | 1032 | 1008 | 1005 | 1005 | Breathing |
|
| ||||||
| 1079 | 1078 | 1065 | 1070 | 1072 | 1072 | C–O |
|
| ||||||
| 1105 | 1104 | 1104 | 1085 | 1089 | 1089 | C–O |
|
| ||||||
| 1123 | 1123 | 1122 | 1109 | 1114 | 1114 | C–O |
|
| ||||||
| 1137 | 1139 | 1136 | 1109 | 1114 | 1114 | C–C |
|
| ||||||
| 1157 | 1157 | 1156 | 1153 | 1143 | 1143 | C–O |
|
| ||||||
| 1206 | 1205 | 1200 | 1194 | 1201 | 1201 | C–O |
|
| ||||||
| 1226 | 1225 | 1221 | 1205 | 1211 | 1211 | CH2
|
|
| ||||||
| — | 1239 | 1239 | 1235 | 1235 | C–O–H | |
|
| ||||||
| 1278 | 1275 | 1275 | 1262 | 1263 | 1263 | C–O–H |
|
| ||||||
| 1291 | 1290 | 1293 | 1289 | 1284 | 1285 | C–O–H |
|
| ||||||
| 1317 | 1317 | 1318 | 1289 | 1284 | 1285 | Breathing |
|
| ||||||
| 1329 | 1329 | 1330 | 1317 | 1318 | 1318 | C–O |
|
| ||||||
| 1367 | 1367 | 1366 | 1374 | 1374 | 1374 | C–C–C |
|
| ||||||
| 1404 | — | — | CH3 sc in COCH3 group | |||
|
| ||||||
| 1425 | 1427 | 1423 | 1404 | 1413 | 1413 | O–C–H |
|
| ||||||
| 1476 | 1476 | 1478 | 1474 | 1471 | 1472 | C–O |
|
| ||||||
| 1502 | 1502 | 1505 | 1506 | 1507 | 1507 | C–O–H |
|
| ||||||
| 1524 | 1524 | 1527 | 1525 | 1524 | C–O–H | |
|
| ||||||
| 1614 | 1615 | 1615 | 1576 | 1582 | 1581 | C–C |
|
| ||||||
| 1640 | 1640 | 1642 | 1576 | 1582 | 1581 | C–C |
|
| ||||||
| 1661 | 1663 | 1663 | 1617 | 1616 | 1616 | NH2 sc |
|
| ||||||
| 1688 | 1688 | 1688 | 1617 | 1616 | 1616 | C=O |
|
| ||||||
| 1744 | 1744 | 1745 | 1707 | 1717 | 1717 | C=O |
|
| ||||||
| 1791 | 1808 | 1807 | 1716 | 1730 | 1730 | C=O |
|
| ||||||
| 2967–3237 | 2844–3108 | C–H | ||||
|
| ||||||
| 3009 | 3010 | 2960 | 2878 | 2896 | 2896 | O–H |
|
| ||||||
| 3488 | 3488 | 3485 | N–H | |||
|
| ||||||
| 3566 | 3566 | 3571 | N–H | |||
|
| ||||||
| 3630 | 3634 | 3639 | 3161 | 3326 | 3329 | O–H |
|
| ||||||
| 3791 | 3788 | 3785 | 3527 | 3527 | O–H | |
|
| ||||||
| 3809 | 3801 | — | O–H | |||
|
| ||||||
| — | 3831 | 3831 | 3545 | 3545 | O–H | |
Vibrational modes—s: stretching, b: bending, w: wagging, sc: scissoring, r: rocking, and t: twisting.
Figure 5FT-IR spectra of unirradiated and gamma irradiated daunorubicin.
Figure 6FT-IR spectra of unirradiated and gamma irradiated doxorubicin.
Figure 7FT-IR spectra of unirradiated and gamma irradiated epidoxorubicin.
Figure 8HPLC profile of unirradiated daunorubicin.
Figure 9HPLC profile of irradiated daunorubicin (25 kGy).
Figure 10HPLC profile of unirradiated doxorubicin.
Figure 11HPLC profile of irradiated doxorubicin (25 kGy).
Figure 12HPLC profile of unirradiated epidoxorubicin.
Figure 13HPLC profile of irradiated epidoxorubicin (25 kGy).